Compare ASTRAZENECA PHARMA with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SHASUN PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SHASUN PHARMA ASTRAZENECA PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 105.4 123.9 85.1% View Chart
P/BV x 30.8 8.5 361.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SHASUN PHARMA
Mar-14
ASTRAZENECA PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,27894 1,356.7%   
Low Rs88346 1,935.5%   
Sales per share (Unadj.) Rs228.4214.2 106.6%  
Earnings per share (Unadj.) Rs10.45.3 194.2%  
Cash flow per share (Unadj.) Rs16.315.8 102.8%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs98.853.3 185.2%  
Shares outstanding (eoy) m25.0056.62 44.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,449.3%   
Avg P/E ratio x104.213.1 795.7%  
P/CF ratio (eoy) x66.44.4 1,503.7%  
Price / Book Value ratio x10.91.3 834.6%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m27,0083,958 682.4%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5352,164 71.0%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71012,127 47.1%  
Other income Rs m123229 53.4%   
Total revenues Rs m5,83312,356 47.2%   
Gross profit Rs m4631,009 45.9%  
Depreciation Rs m147594 24.8%   
Interest Rs m0415 0.0%   
Profit before tax Rs m438230 190.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-73 -246.0%   
Profit after tax Rs m259302 85.8%  
Gross profit margin %8.18.3 97.4%  
Effective tax rate %40.8-31.7 -129.0%   
Net profit margin %4.52.5 182.1%  
BALANCE SHEET DATA
Current assets Rs m3,2096,884 46.6%   
Current liabilities Rs m2,0708,456 24.5%   
Net working cap to sales %20.0-13.0 -154.0%  
Current ratio x1.60.8 190.5%  
Inventory Days Days7262 117.4%  
Debtors Days Days35108 32.5%  
Net fixed assets Rs m7904,970 15.9%   
Share capital Rs m50113 44.1%   
"Free" reserves Rs m2,4192,875 84.2%   
Net worth Rs m2,4693,020 81.8%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m4,60513,347 34.5%  
Interest coverage xNM1.6-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.9 136.5%   
Return on assets %5.65.4 104.7%  
Return on equity %10.510.0 104.9%  
Return on capital %17.713.3 133.1%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m3005,843 5.1%   
Fx outflow Rs m2,0152,173 92.7%   
Net fx Rs m-1,7153,669 -46.7%   
CASH FLOW
From Operations Rs m88398 22.1%  
From Investments Rs m-94-1,635 5.7%  
From Financial Activity Rs mNA1,309 0.0%  
Net Cashflow Rs m-671 -8.0%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.6 8.3%  
FIIs % 15.7 17.6 89.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 39.6 23.0%  
Shareholders   12,856 20,750 62.0%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 224 Points Higher; Realty and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 29, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS